Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/jgs.17416 http://scihub22266oqcxt.onion/10.1111/jgs.17416 34375437!8447437!34375437     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Am+Geriatr+Soc 2021 ; 69 (11): 3023-3033 Nephropedia Template TP {{tp|p=34375437|t=2021. Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era |pdf=|usr=}}{{34375437}} gab.com Text Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era JO: J Am Geriatr Soc http://www.kidney.de/pget.php?&tw=1&pmid=34375437 #FOAvip The burden of senescent cells (SnCs), which do not divide but are metabolically active and resistant to death by apoptosis, is increased in older adults and those with chronic diseases. These individuals are also at the greatest risk for morbidity and mortality from SARS-CoV-2 infection. SARS-CoV-2 complications include cytokine storm and multiorgan failure mediated by the same factors as often produced by SnCs through their senescence-associated secretory phenotype (SASP). The SASP can be amplified by infection-related pathogen-associated molecular profile factors. Senolytic agents, such as Fisetin, selectively eliminate SnCs and delay, prevent, or alleviate multiple disorders in aged experimental animals and animal models of human chronic diseases, including obesity, diabetes, and respiratory diseases. Senolytics are now in clinical trials for multiple conditions linked to SnCs, including frailty; obesity/diabetes; osteoporosis; and cardiovascular, kidney, and lung diseases, which are also risk factors for SARS-CoV-2 morbidity and mortality. A clinical trial is underway to test if senolytics decrease SARS-CoV-2 progression and morbidity in hospitalized older adults. We describe here a National Institutes of Health-funded, multicenter, placebo-controlled clinical trial of Fisetin for older adult skilled nursing facility (SNF) residents who have been, or become, SARS-CoV-2 rtPCR-positive, including the rationale for targeting fundamental aging mechanisms in such patients. We consider logistic challenges of conducting trials in long-term care settings in the SARS-CoV-2 era, including restricted access, consent procedures, methods for obtaining biospecimens and clinical data, staffing, investigational product administration issues, and potential solutions for these challenges. We propose developing a national network of SNFs engaged in interventional clinical trials. Twit Text FOAVip Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era ????J Am Geriatr Soc http://www.kidney.de/pget.php?&tw=1&pmid=34375437 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34375437 #FOAvip English Wikipedia <ref>{{Cite pmid|34375437}}</ref> Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era #MMPMID34375437 Verdoorn BP; Evans TK; Hanson GJ; Zhu Y; Langhi Prata LGP; Pignolo RJ; Atkinson EJ; Wissler-Gerdes EO; Kuchel GA; Mannick JB; Kritchevsky SB; Khosla S; Rizza SA; Walston JD; Musi N; Lipsitz LA; Kiel DP; Yung R; LeBrasseur NK; Singh RJ; McCarthy T; Puskarich MA; Niedernhofer LJ; Robbins PD; Sorenson M; Tchkonia T; Kirkland JL J Am Geriatr Soc 2021[Nov]; 69 (11): 3023-3033 PMID34375437show ga The burden of senescent cells (SnCs), which do not divide but are metabolically active and resistant to death by apoptosis, is increased in older adults and those with chronic diseases. These individuals are also at the greatest risk for morbidity and mortality from SARS-CoV-2 infection. SARS-CoV-2 complications include cytokine storm and multiorgan failure mediated by the same factors as often produced by SnCs through their senescence-associated secretory phenotype (SASP). The SASP can be amplified by infection-related pathogen-associated molecular profile factors. Senolytic agents, such as Fisetin, selectively eliminate SnCs and delay, prevent, or alleviate multiple disorders in aged experimental animals and animal models of human chronic diseases, including obesity, diabetes, and respiratory diseases. Senolytics are now in clinical trials for multiple conditions linked to SnCs, including frailty; obesity/diabetes; osteoporosis; and cardiovascular, kidney, and lung diseases, which are also risk factors for SARS-CoV-2 morbidity and mortality. A clinical trial is underway to test if senolytics decrease SARS-CoV-2 progression and morbidity in hospitalized older adults. We describe here a National Institutes of Health-funded, multicenter, placebo-controlled clinical trial of Fisetin for older adult skilled nursing facility (SNF) residents who have been, or become, SARS-CoV-2 rtPCR-positive, including the rationale for targeting fundamental aging mechanisms in such patients. We consider logistic challenges of conducting trials in long-term care settings in the SARS-CoV-2 era, including restricted access, consent procedures, methods for obtaining biospecimens and clinical data, staffing, investigational product administration issues, and potential solutions for these challenges. We propose developing a national network of SNFs engaged in interventional clinical trials. |*COVID-19 Drug Treatment[MESH] |*Skilled Nursing Facilities[MESH] |Aged[MESH] |COVID-19/prevention & control[MESH] |Cellular Senescence/*drug effects[MESH] |Clinical Trials as Topic[MESH] |Drug Monitoring[MESH] |Flavonols/*therapeutic use[MESH]Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials i(epmc).pdf DeepDyve Pubget Overpricing